Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Tumor-informed testing relies upon either previous or simultaneous ... we will review the current available evidence assessing this application as well as various other platforms in urothelial ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

The frequency of polyp diagnoses in close relatives was strongly associated with colorectal cancer risk. Polyp history in second-degree relatives was only influential with multiple polyp diagnoses.

Of particular interest is the silencing of tumor-suppressor genes by epigenetic alteration. Recent progress in understanding epigenetic modification and gene silencing has led to new opportunities ...

The growing sophistication of tumor molecular profiling has helped to slowly transition ... The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB ...

Frequent colorectal polyp diagnoses in first- and second-degree relatives are associated with an increased risk for colorectal cancer (CRC), especially early-onset CRC. Researchers evaluated the ...